Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 11/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.41 |
| ▸ | WNT1 | P04628 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28897472 | 1.00 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1GSK3BDYRK1AWNT1 | |
| SCHEMBL21061673 | 0.86 | WNT1 (0.41) | L3MBTL1GSK3BDYRK1AWNT1LMNA | |
| SCHEMBL21645195 | 0.80 | CHRM1 (0.44) | L3MBTL3L3MBTL1SMN1; SMN2LMNAHRH3 | |
| SCHEMBL28449108 | 0.79 | TSHR (0.51) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28444960 | 0.79 | GSK3B (0.39) | L3MBTL3L3MBTL1GSK3BDYRK1AWNT1 | |
| SCHEMBL28968906 | 0.79 | TSHR (0.51) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28447489 | 0.79 | GSK3B (0.39) | L3MBTL3L3MBTL1GSK3BDYRK1AWNT1 | |
| SCHEMBL28456680 | 0.79 | GSK3B (0.39) | L3MBTL3L3MBTL1GSK3BDYRK1AWNT1 | |
| SCHEMBL13291086 | 0.78 | TSHR (0.53) | L3MBTL3L3MBTL1SMN1; SMN2LMNAPRCP | |
| SCHEMBL364361 | 0.77 | HDAC1 (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111479813-B | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2023-03-21 | — | — | CN | disclosed |
| EP-3724192-B1 | TRIAZOLOBENZAZEPINES AS VASOPRESSIN V1A RECEPTOR ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2022-08-03 | — | — | EP | disclosed |
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | RICHTER GEDEON NYRT. (HU) | 2022-04-12 | — | — | US | disclosed |
| CN-111479813-A | Triazolobenzazepines as vasopressin V1A receptor antagonists | 吉瑞工厂 | 2020-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11298363-B2 | Triazolobenzazepines as vasopressin V1a receptor antagonists | AVPR1B, AVPR1A, AVPR2 | L3MBTL3 3605/4885L3MBTL1 3344/4885GSK3B 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.